|
|||||
|
|
Phase II trial of piroxantrone in gastric carcinoma |
|
| Authors: | Alexander Hantel Catherine Tangen William L. Gluck John S. Macdonald |
| Affiliation: | (1) Loyola University Stritch School of Medicine, Maywood, IL;(2) Southwest Oncology Group Statistical Center, Seattle, WA;(3) Greenville Cancer Center, Greenville, SC;(4) Temple University, Philadelphia, PA, USA |
| Abstract: | Summary Twenty-one evaluable patients with advanced gastric adenocarcinoma were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. One objective response was seen for an overall response rate of 5% (95% confidence interval 0–24%). Toxicities of grade  3 were primarily hematologie and seen in 13/21 patients. Piroxantrone has minimal activity against gastric adenocarcinoma and no further investigation of this agent on this schedule in this disease is recommended. |
| Keywords: | piroxantrone gastric adenocarcinoma |
| 本文献已被 SpringerLink 等数据库收录！ | |